From the JAMA Network: Over-the-Counter Hearing Aid–Enabled Earbuds

Superficial vein thrombosis (SuVT) is characterized by thrombus formation in the superficial veins, typically in the lower or upper extremities. In this podcast, the coauthor of a JAMA review on SuVT, Behnood Bikdeli, MD, MS, discusses pathophysiology, risk factors, diagnosis, and treatment of SuVT with JAMA Deputy Editor Mary McDermott, MD. Related Content: Superficial Vein Thrombosis

Untreated hypothyroidism can cause serious health complications such as heart failure and myxedema coma. Author Maria Papaleontiou, MD, of the University of Michigan joins JAMA Senior Editor Karen Lasser, MD, MPH, to discuss the current evidence regarding the epidemiology, diagnosis, clinical presentation, and treatment of primary overt hypothyroidism in nonpregnant adults. Related Content: Hypothyroidism

Interview with Alexander Chern, MD, author of Over-the-Counter Hearing Aid–Enabled Earbuds—Merging Hearing Health and Technology. Hosted by Paul C. Bryson, MD, MBA. Related Content: Over-the-Counter Hearing Aid–Enabled Earbuds—Merging Hearing Health and Technology

The incidence and prevalence of cutaneous melanoma in the US and worldwide have increased over the last 5 decades. JAMA Review Author John Kirkwood, MD, discusses the epidemiology, risk factors, treatment, and prevention of melanoma with JAMA Deputy Editor Kristin Walter, MD, MS. Related Content: Cutaneous Melanoma ----------------------------------- JAMA Editors' Summary

Hemorrhoidal disease, pathology of the tissue lining the anal canal, affects approximately 10 million individuals in the US. Author Jean H. Ashburn, MD, of Wake Forest University School of Medicine and JAMA Senior Editor Karen E. Lasser, MD, MPH, discuss the current evidence on the epidemiology, pathophysiology, diagnosis, and treatment of hemorrhoidal disease. Related Content: Hemorrhoidal Disease ----------------------------------- JAMA Editors' Summary

Dalbavancin, a long-acting IV lipoglycopeptide, may be an option for the treatment of complicated Staphylococcus aureus bacteremia without requiring long-term IV access. Author Thomas L. Holland, MD, MSc, from Duke University School of Medicine discusses key points of the DOTS randomized clinical trial and more with JAMA Deputy Editor Preeti Malani, MD, MSJ. Related Content: Dalbavancin for Treatment of Staphylococcus aureus Bacteremia Management of Staphylococcus aureus Bacteremia ----------------------------------- JAMA Editors' Summary

Prostatitis affects approximately 9.3% of men in their lifetime and includes acute and chronic bacterial infection and nonbacterial chronic prostatitis with chronic pelvic pain syndrome. Author Minh N. Pham, MD, from University of North Carolina School of Medicine discusses this and more with JAMA Deputy Editor Mary M. McDermott, MD. Related Content: Prostatitis ----------------------------------- JAMA Editors' Summary

Geroscience aims to define and modify biologic pathways associated with aging and age-related diseases. Author Stephen B. Kritchevsky, PhD, of the Wake Forest University School of Medicine and JAMA Deputy Editor Mary M. McDermott, MD, discuss current evidence regarding geroscience, human health, and promising therapies that may slow aging and age-related decline. Related Content: Geroscience ----------------------------------- JAMA Editors' Summary

New medications for obesity, such as semaglutide and tirzepatide, are highly effective but can be associated with adverse effects that reduce adherence. Obesity expert and author Robert Kushner, MD, joins JAMA Deputy Editor Mary McDermott, MD, to discuss a recent JAMA Insights article on managing adverse effects of obesity medications. Related Content: Managing Adverse Effects of Incretin-Based Medications for Obesity ----------------------------------- JAMA Editors' Summary

A patent foramen ovale (PFO) is present in approximately 25% of all adults. Author David M. Kent, MD, MS, of Tufts Medical Center and JAMA Associate Editor David Simel, MD, MHS, discuss how to evaluate the likelihood that a PFO was causal in a patient with a cryptogenic ischemic stroke, and closure of a PFO to lower the incidence of recurrent strokes for affected patients. Related Content: Patent Foramen Ovale and Stroke Patent Foramen Ovale and Dysarthria in a Man in His 60s Management of Patients With a Patent Foramen Ovale With History of Stroke or TIA Heterogeneity of Treatment Effects in an Analysis of Pooled Individual Patient Data From Randomized Trials of Device Closure of Patent Foramen Ovale After Stroke Transesophageal Echocardiogram Detecting a High-Risk Patent Foramen Ovale ----------------------------------- JAMA Editors' Summary